FDA Approves Mirabegron, Solifenacin Combo for OAB FDA Approves Mirabegron, Solifenacin Combo for OAB
The FDA has approved mirabegron (Myrbetriq, Astellas Pharma) in combination with solifenacin succinate for the treatment of overactive bladder (OAB).FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Urology News Alert Source Type: news
More News: Health | Overactive Bladder | Overactive Bladder Syndrome | Pharmaceuticals | Urology & Nephrology | VESIcare